You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al

Citation Tools

Article menu

Download PDFPDF

Letter
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Weber J, Mandala M, Ascierto PA, et al
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al
Journal for ImmunoTherapy of Cancer 2022;10:e004347. doi: 10.1136/jitc-2021-004347